AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02717455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria.
Study NCT03610230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
Study NCT03610230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Isomaltoside
Description: Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
Study NCT03610230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: the currently most widely used intravenous iron preparation with good safety profile
Study NCT03610230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: the currently most widely used intravenous iron preparation with good safety profile
Study NCT04142086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
Study NCT03135041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber-containing dietary supplement
Description: Effects of fiber-containing dietary supplement on weight loss during energy restriction
Study NCT04142086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
Study NCT04142086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
Study NCT04142086 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
Study NCT03135041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effects of placebo supplement on weight loss during energy restriction
Study NCT03873987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current Formulation of Oritavancin
Description: Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
Study NCT03873987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kimyrsa
Description: New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
Study NCT01199211 — intervention group
Intervention type: OTHER
Intervention: Exercise training, women, marathon
Description: Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
Study NCT00762398 — intervention group
Intervention type: DEVICE
Intervention: Masimo hemoglobin-meter
Description: Placing a probe on the finger
Study NCT00762398 — intervention group
Intervention type: BIOLOGICAL
Intervention: drawing blood sample
Description: drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
Study NCT02706444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon angioplasty
Description: After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
Study NCT02706444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated Balloon angioplasty
Description: After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
Study NCT01824381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Place amniotic membrane in large wounds
Description: After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times.
Study NCT01824381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obtaining and Cryopreservation of amniotic membrane
Study NCT01824381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amniotic membrane
Study NCT01756183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 + Paclitaxel Chemotherapy
Description: Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1
Study NCT00663754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dissonance-based eating disorder prevention program
Description: Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
Study NCT00663754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational brochure
Description: Participants will receive a mailed educational brochure about a healthy body image only.
Study NCT03522220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D navigation video game intervention
Description: Participants intensively train with a video game (Super Mario DS)
Study NCT03522220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video game intervention without 3D navigation
Description: Participants train with a video game (Super Mario Bros)
Study NCT03522220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No 3D navigation
Description: Participants read on a kindle device (control group)
Study NCT00544791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 5 mg, oral, daily dose for 6 months
Study NCT00544791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo like melatonin tablets
Study NCT02830321 — intervention group
Intervention type: OTHER
Intervention: helicopacter pylori stool antigen test (CER TEST BIOTEC)
Description: Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
Study NCT03700489 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
Study NCT03700489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
Study NCT03487497 — intervention group
Intervention type: PROCEDURE
Intervention: Lateral column lengthening osteotomy
Description: Lengthening osteotomy of the lateral column of the foot
Study NCT00612560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg per day
Study NCT00612560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: 25 g per day ground
Study NCT00612560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill 1 per day
Study NCT03579043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritive Sweetener
Description: Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
Study NCT03579043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Nutritive Sweetener
Description: Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
Study NCT00580502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAP-BAND® Adjustable Gastric Band (LAGB®)
Description: Bariatric surgery for patient whose BMI is between 30 and 40 kg/m\^2
Study NCT00713037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoromisonidazole-PET/CT
Description: 2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
Study NCT00430586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
Study NCT01980030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study NCT02920671 — intervention group
Intervention type: OTHER
Intervention: Tracer-enhanced oral glucose tolerance test (OGTT*)
Description: Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
Study NCT02920671 — intervention group
Intervention type: OTHER
Intervention: Muscle MRI
Description: Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
Study NCT02920671 — intervention group
Intervention type: OTHER
Intervention: Dual energy x-ray absorptiometry (DXA)
Description: DXA will be performed to evaluate body composition.
Study NCT02920671 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires will be used to evaluate participants' health and habits.
Study NCT00590616 — intervention group
Intervention type: PROCEDURE
Intervention: transthoracic examination
Description: observational transthoracic examination
Study NCT03689465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TRU-015
Description: IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
Study NCT03689465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
Study NCT03689465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
Study NCT03689465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin A (CsA)
Description: In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
Study NCT03689465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate (MTX)
Description: In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
Study NCT02171195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
Study NCT00634933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
Study NCT02171195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo administered as oral tablets with 200 ml potable water.
Study NCT03846323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visiting policies: 24 hours a day, 7 days a week
Study NCT03846323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Restriction of visiting policies < 6 hours
Study NCT00664729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Reduced calorie diet (400 kcal/day deficit)
Study NCT00664729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction + Low-Intensity aerobic exercise
Description: 400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
Study NCT00664729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction plus High-intensity aerobic exercise
Description: 400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
Study NCT03778281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
Study NCT03778281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyclopramide
Description: Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
Study NCT00843128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted gait training (RAGT)
Description: 20 patients will be treated with RAGT, 12 sessions over three weeks.
Study NCT00843128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional walking training (CWT)
Description: The control group will be treated by CWT, 12 sessions in three weeks.
Study NCT01349816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days
Study NCT01444261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fer-in-Sol
Description: Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
Study NCT01444261 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: No dietary supplements
Study NCT03027024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of IOL: PhysIOL POD F GF
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material
Study NCT02939794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
Study NCT02939794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (normal saline, sodium chloride)
Study NCT02756611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablets for oral administration
Study NCT03399045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 9-minute withdrawal
Description: Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
Study NCT03399045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute withdrawal
Description: Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
Study NCT03092219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA Redensity
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
Study NCT00790725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proportional Assist Ventilation
Description: Proportional Assist Ventilation will be used to ventilate the patients.
Study NCT00790725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pressure Support Ventilation
Description: Pressure Support ventilation will be used to ventilate the patients.
Study NCT03579043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbonated Water
Description: Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
Study NCT00487071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Study NCT01645410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Study NCT01645410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited